تداخل‌های دارویی
Clarithromycin + Simvastatin
شدت: منع مصرف
Clarithromycin and Simvastatin: contraindicated interaction.
آخرین به‌روزرسانی منابع: US FDA label
ویژه کادر درمان — فقط جهت مرجع. این صفحه خلاصه‌ای کوتاه است، توصیه پزشکی نیست و جایگزین بروشور رسمی یا قضاوت بالینی نمی‌شود. پیش از تجویز یا تحویل دارو همیشه بررسی کنید.
محتوای بالینی این صفحه فقط به زبان انگلیسی موجود است.
خلاصه
Clarithromycin substantially increases simvastatin acid exposure and raises the risk of myopathy and rhabdomyolysis, which may lead to acute kidney injury. The combination is contraindicated in simvastatin labeling. Older patients, those with renal impairment or on higher simvastatin doses are at greatest risk.
معنای این تداخل به زبان ساده
Clarithromycin and Simvastatin are not normally used together. Taking them at the same time is expected to cause harm or make one of them unsafe, so a different medicine is usually chosen for one of the two.
Clarithromycin belongs to Anti Bacterial; Simvastatin belongs to Cardiovascular.
چرا رخ می‌دهد
Clarithromycin is a strong CYP3A4 inhibitor (and P-gp inhibitor), reducing the first-pass and systemic metabolism of simvastatin and its active acid.
اقدام لازم
Do not use together; suspend simvastatin for the duration of clarithromycin therapy, or use an alternative antibiotic such as azithromycin. For short courses, temporary interruption is usually preferred; pravastatin or rosuvastatin are options if statin continuation is essential.
از داروساز چه بپرسید
- Is there an alternative to one of these two medicines for me?
- If both are essential, who is monitoring me and how often?
- Which symptoms mean I should stop and seek help straight away?
ویژه اعضای Pro+
باز کردن کل صفحه
یک حساب بسازید و دوره آزمایشی Pro+ را شروع کنید تا توصیه‌های کامل مدیریت Clarithromycin و Simvastatin، یادداشت‌های تکمیلی، جزئیات شواهد و بررسی‌کننده تداخل برای کل نسخه را باز کنید.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Pro+ را ۱۴ روز رایگان در وب امتحان کنید. بدون نیاز به کارت.
منابع
تداخلات دیگر Simvastatin
- Atazanavir + Simvastatin منع مصرف
- Cobicistat + Simvastatin منع مصرف
- Cyclosporine + Simvastatin منع مصرف
- Cyclosporin + Simvastatin منع مصرف
- Danazol + Simvastatin منع مصرف
- Darunavir + Simvastatin منع مصرف
تداخلات دیگر Clarithromycin
- Astemizole + Clarithromycin منع مصرف
- Avanafil + Clarithromycin منع مصرف
- Cisapride + Clarithromycin منع مصرف
- Clarithromycin + Colchicine منع مصرف
- Clarithromycin + Conivaptan منع مصرف
- Clarithromycin + Dihydroergotamine منع مصرف
پرسش‌های متداول
Can I take Clarithromycin with Simvastatin?
MediHelp rates the interaction as contraindicated. Clarithromycin and Simvastatin are not normally used together. Taking them at the same time is expected to cause harm or make one of them unsafe, so a different medicine is usually chosen for one of the two. Clarithromycin substantially increases simvastatin acid exposure and raises the risk of myopathy and rhabdomyolysis, which may lead to acute kidney injury. The combination is contraindicated in simvastatin labeling. Older patients, those with renal impairment or on higher simvastatin doses are at greatest risk.
How serious is the interaction between Clarithromycin and Simvastatin?
MediHelp rates it contraindicated, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Do not use together; suspend simvastatin for the duration of clarithromycin therapy, or use an alternative antibiotic such as azithromycin. For short courses, temporary interruption is usually preferred; pravastatin or rosuvastatin are options if statin continuation is essential.
What other medicines interact with Simvastatin?
MediHelp also lists interactions of Simvastatin with, for example, Atazanavir, Cobicistat, Cyclosporine. The full list is on the Simvastatin page.
تک‌نگاری کامل، دوزاژ و بررسی تداخل دارویی در برنامه MediHelp
مرجع کامل را باز کنید، تداخل چند دارو را بررسی کنید و از ابزارهای دوز در برنامه MediHelp استفاده کنید.
